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ABSTRACT 
Objective: To develop and validate macitentan with its known and unknown degradation impurities in its tablet dosage form.  
Methods: The RP-HPLC method for macitentan and its impurities was developed and three potential degradation impurities MCA-02, MCA-01 and 
degradation impurity and N-propyl derivative and N-N dimethyl derivative process impurities were separated. Chromatographic separation was 
achieved within 70 min on Inertsil C8 (250*4.6 mm, 5 µm) column, Using mobile phase A [Ammonium acetate (ph 4.5 adjusted with glacial acetic 
acid)] and mobile phase B acetonitrile in gradient elution. Other hplc parameter which was optimized flow rate 1.5 ml/min, detection wavelength 
266 nm, column oven temperature 30 ° C and injection volume 20μl. macitentan was subjected to forced degradation also known as stress testing. It 
was validated as per ICH guidelines.  
Results: The drug showed extensive degradation in acidic and basic conditions, a slight degradation in oxidative condition. The developed method 
was statistically validated for linearity (0.45-2.25 ppm). The result of precision (%RSD<5), robustness, LOD(0.15 ppm) and LOQ(0.45 ppm) are well 
within limits.% Recovery at LOQ, 50%, 100% and 150% was found to be within limit 80-120 %.  
Conclusion: RP-HPLC method was successfully developed with satisfactory separation of macitentan and its impurities. The proposed method was 
found to be specific, accurate, precise and robust can be used for estimation of macitentan and its impurities and can be successfully employed in 
the routine analysis of macitentan. 
Keywords: RP-HPLC, Macitentan, Forced Degradation 




Macitentan is chemically a {[5-(4-bromophenyl)-6-{2-[(5-bromo-
pyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfamoyl}(propyl) amine) 
with molecular weight of 588.273g/mol [1]. 
Macitentan blocks the ET1-dependent rise in intracellular calcium 
by inhibiting the binding of ET-1 to ET receptors. Blocking of the 
ETA receptor subtype seems to be of more importance in the 
treatment of PAH than blocking of ETB, likely because there are 
higher numbers of ETA receptors than ETB receptors in pulmonary 
arterial smooth muscle cells [2-4]. 
A survey of literature revealed that RP-HPLC, first order Derivative 
UV Spectroscopy, and stability indicating analytical methods have 
been reported for macitentan. On literature survey, it was found that 
there are few RP-HPLC analytical methods available, but in my work 
impurities to be estimated are other than the reported one. Hence it 
was thought worthwhile to develop a method for estimation of 
impurities and related substance in macitentan using HPLC [5-9]. 
Therefore, it was of thought interest to develop precise, accurate, 
sensitive, selective chromatographic method for estimation of 
macitentan in Tablet dosage form which will provide valuable 
information that can be used to assess the inherent stability of the 
drug under various stressed conditions, eventually to improve 
formulation and manufacturing process. The aim of work was to 
carry out RP-HPLC method development and validation for 
macitentan tablet dosage form [10-12]. 
 
 
Fig. 1: Structure of macitentan 
 
MATERIALS AND METHODS  
In the present research work, an attempt was made to develop and 
validate macitentan tablet dosage form with its Known and 
unknown Degradation Impurities with RP-HPLC method. 
acetonitrile, methanol, ammonium acetate, potassium hydrogen 
Phosphate, hydrochloric acid, sodium hydroxide, hydrogen peroxide, 
glacial acetic acid and phosphoric Acid were produce from Merck. 
The sample of Macitentan API, Tablets and impurities were kindly 
gifted by ZYDUS CADILA HEALTH CARE, Moraiya, Ahmedabad [13]. 
 
Table 1: List of Impurities with their specification 
S. No. Impurity Acceptance criteria 
1  (MCA-01) Not more than 0.15% 
2  (MCA-02) Not more than 0.15% 
3  (Degradation) Not more than 0.15% 
4  (N-propyl derivative) Not more than 0.10% 
5  (N-N Dimethyl derivative) Not more than 0.15% 
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The analysis was performed on HPLC Agilent technologies 1200 series, 
fitted with a gradient pump photodiode array detector and rheodyne 
injector with 20μl loop volume. Inertsil C8 (250 mm *4.6 mm)5 µm) 
column which is maintained at 30 ° C temperature. Chem-station 
software was applied for data collecting and processing. 
Preparation of mobile phase 
Prepare a Mobile phase A [Ammonium acetate (ph 4.5 adjusted with 
glacial acetic acid)] and Mobile phase B Acetonitrile in gradient 
elution. A buffer was sonicated for 5 min (minute) for degassing and 
filtered through 0.45 µ Millipore filter. 
Diluent 
The drug was dissolved in acetonitrile. 
Preparation of standard stock solution (200 ppm) 
Transfer an accurately weighed quantity of about 20 mg of 
Macitentan working standard into 100 ml of volumetric flask. Add 
about 50 ml of diluent and sonicate to dissolve. Make the volume up 
to mark with diluent and mix. 
Preparation of standard solution (10 ppm) 
Take 5 ml from std. A stock solution was transferred into the 100 ml 
volumetric flask and then diluted with the diluents. 
Preparation of impurities solution: (10 ppm) 
MCA-01: Weigh 1.012 mg of MCA-01 dissolve in 10 ml of diluent 2. 
Take 1 ml of it and dissolve in 10 ml diluents and mix well. 
MCA-02: Weigh 1.005 mg of MCA-02 dissolve in 10 ml of diluent 2. 
Take 1 ml of it and dissolve in 10 ml diluents and mix well. 
Degradation impurity: Weigh 1.003 mg of degradation impurity 
dissolve in 10 ml of diluent 2. Take 1 ml of it and dissolve in 10 ml 
diluents and mix well. 
N-N Dimethyl derivative impurity: Weigh 1.042 mg of N-N Dimethyl 
derivative impurity dissolve in 10 ml of diluent 2. Take 1 ml of it and 
dissolve in 10 ml diluents and mix well. 
N-propyl derivative: Weigh 1.023 mg of N-propyl derivative 
impurity dissolve in 10 ml of diluent 2. Take 1 ml of it and dissolve 
in 10 ml diluents and mix well. 
(Diluent 2: 0.05% v/v HCL in ACN) 
Spiked impurity mixture: (Specification limit of impurities 
=0.15 %) 
Take 1 ml of the stock solution of standard, 1 ml of MCA-01 Stock 
solution, 1 ml of MCA-02 solution, 1 ml of Degradation impurity solution, 
1 ml of N-N Dimethyl derivative impurity solution, 1 ml of N Propyl 
derivative impurity solution dilute up to 20 ml with ACN. Filter solution 
with 0.45 µm PVDF Filter. 
As such sample preparation: (1000 ppm) 
[label claim: 10 mg] 
The average of 10 Tablet was determined and grounded in a mortar. 
Weigh and transfer crush tablet equivalent to 50 mg (182.3 mg) into 
50 ml of volumetric flask. Add 30 ml diluent (ACN) and sonicate for 
45 min and makeup to 50 ml with diluents Mix well. Filter with 0.45 
µm PVDF Filter. 
Chromatographic conditions 
Inertsil C8 (250*4.6 mm, 5 µm column was used as the stationary 
phase. Using mobile phase A [Ammonium acetate (ph 4.5 adjusted 
with glacial acetic acid)] and mobile phase B Acetonitrile in gradient 
elution It was filtered through 0.45μ (micron) membrane filter and 
degassed. The mobile phase was pumped at 1.5 ml/min. The eluents 
were monitored at 266 nm. The injection volumes of sample and 
standard were 20μl (microliter). Total run time is 70 min. 
 
Table 2: Gradient program 
Time MP A MP B 
0 66 34 
5 66 34 
15 60 40 
30 50 50 
50 40 60 
60 25 75 
62 66 34 
70 66 34 
 
 
Fig. 2: Chromatogram of macitentan with its impurities 
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The developed Method was validated for linearity, precision, 
accuracy, robustness and is applied for forced degradation studies as 
per the ICH guidelines. 
RESULTS AND DISCUSSION 
Method development  
ICH prescribed stress conditions such as acidic, basic and oxidative 
stresses were carried out. 
Acid degradation 
Sample preparation 
The average of 10 Tablet was determined and grounded in a mortar. 
An accurately weighed the amount of powder equivalent to 10 mg of 
macitentan (152.5 mg) sample dissolve in 10 ml of diluent (ACN) 
sonicate for 30 min then add 1 ml of 5 N HCL and heat at 80 ° C in 
water bath for 1 h. Then cool it at RT and neutralize it with 1 ml of 5 
M NaOH. Makeup to volume 25 ml with Diluent. Filter it. 
 
 
Fig. 3: Acid degradation for macitentan 
 
Base degradation 
Preparation of sample 
The average of 10 Tablet was determined and grounded in a 
mortar. An accurately weighed the amount of powder equivalent 
to 10 mg of macitentan (152.6 mg) sample dissolve in 10 ml of 
diluent (ACN) sonicate for 30 min then add 1 ml of 5 M NaOH and 
heat at 80 ° C in a water bath for 1 h. then cool it at RT and 
neutralize it with 1 ml of 5 N HCL. Make up to volume 25 ml with 
Diluent. Filter it. 
 
 
Fig. 4: Base degradation for macitentan 
 
 
Fig. 5: Peroxide degradation for macitentan 
 
Table 3: Degradation summary 
Type Solution Area %Degradation 
As Such macitentan 159223 - 
Acid Degradation  macitentan 136124 14.50% 
Base Degradation macitentan 141223 11.30% 
Peroxide Degradation macitentan 150013 5.78% 
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Preparation of sample 
152.5 mg sample dissolve in 10 ml with diluents sonicate for 30 min 
then add 1 ml of 10% H2O2 and heat at 80 ° C in a water bath for 1 h then 
cool the sample at RT and make up a sample with Diluent. Filter it. 
Method validation  
The described method has been validated which include parameters 
like linearity, accuracy, precision, robustness, LOD (limit of 
detection) and LOQ (limit of quantification). 
Linearity 
The linearity of this method was evaluated by linear regression 
analysis and calculated by a least square method and studied by 
preparing stock solutions of MCA-01, MCA-02 and Degradation 
impurities at different concentration levels.  
The calibration curve showed good linearity in the range of 0.45-
2.25μg/ml. Generate linearity plot of area versus percentage of 
concentration. Linearity curve it should be more than 0.998 that 
shows linear detector response. The results are given in table 4. 
 
Table 4: Linearity data for MCA-02, MCA-01 and degradation impurity 
Drug Conc* (µg/ml) Area 


















Fig. 6: Calibration curve of MCA-02 
 
 
Fig. 7: Calibration curve of MCA-01 
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Fig. 8: Calibration curve of degradation impurity 
 
Table 5: Recovery data of MCA-02 
Conc 
level 













0.97 0.45 11345 0.466 103.55 
0.45 11234 0.461 102.44 
 
50 % 
0.75 18138 0.745 99.33 97.37±0.33  
0.34 0.75 18098 0.743 99.06 
0.75 18212 0.748 99.73 
 
100 % 
1.5 35735 1.46 97.33 97.77±0.381  
0.38 1.5 35918 1.47 98.00 
1.5 35824 1.47 98.00 
 
150 % 
2.25 54554 2.24 99.55 99.40±0.254  
0.25 2.25 54312 2.23 99.11 
2.25 54624 2.24 99.55 
SD*-Standard deviation, RSD*-relative standard deviation, number of experiments (n)-3 
 
Table 6: Recovery data of MCA-01 
Conc 
level 
Amount added Area observed Amount recovered % 
recovery 




0.45 16212 0.472 104.8 105.46±1.15  
1.09 0.45 16524 0.481 106.8 
0.45 16224 0.472 104.8 
 
50 % 
0.75 25233 0.735 98 98.00±0.230  
0.24 0.75 25148 0.732 97.6 
0.75 25255 0.735 98 
 
100 % 
1.5 50021 1.457 97.13 97.00±0.231  
0.24 1.5 49812 1.451 96.73 
1.5 50013 1.457 97.13 
 
150 % 
2.25 74334 2.165 96.22 96.01±0.045  
0.05 2.25 74331 2.164 96.17 
2.25 74282 2.163 96.13 
Number of experiments (n)–3, SD*-Standard deviation, RSD*-Relative Standard deviation 
 
Table 7: Recovery data of degradation impurity 
Conc 
level 






0.45 9118 0.411 91.33 91.34±1.110  
1.22 0.45 9013 0.406 90.22 
0.45 9228 0.416 92.44 
 
50 % 
0.75 15830 0.714 95.20 95.82±0.669  
0.70 0.75 15911 0.718 95.73 
0.75 16045 0.724 96.53 
 
100 % 
1.5 33586 1.514 100.9 101.00±0.655  
0.64 1.5 33816 1.526 101.7 
1.5 33404 1.507 100.4 
 
150 % 
2.25 51151 2.309 102.6 102.56±0.251  
0.24 2.25 50998 2.302 102.3 
2.25 51258 2.313 102.8 
SD*-Standard deviation, Conc*-concentration, RSD*-Relative Standard deviation, Number of experiments (n)-3 
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The accuracy of the method was determined at LOQ (30%), 50%, 
100% and 150% by calculating recovery of Impurities in the 
solution. Each solution was injected in triplicate and the % recovery 
was calculated. Recovery (individually) at each level is between 91–
106 %. RSD of % recovery is not more than 5. The results are given 
in table 5-7. 
Limit of detection (LOD) and limit of quantification (LOQ) 
According to the ICH recommendation, the approach based on the 
standard deviation (SD) of the response and slope was a use of the 
determining the LOD and LOQ values. 
The LOD and LOQ were found to be 0.15µg/ml and 0.45µg/ml for 
MCA-01, MCA-02 and Degradation impurity estimated by using the 
S/N ratio. The low values of LOD and LOQ illustrate that the 
developed method was sensitive, accurate and precise as it can be 
detected and quantify with very low concentration.  
Acceptance criteria: LOQ 
It is estimated the progressive lower concentration of impurity until 
a signal to noise (S/N) ratio remains greater than 10. 
LOD 
It is estimated by injecting the diluted concentration until the peak 
of impurity is able to detect. The results are given in table 8. 
 
Table 8: S/N Ratio for LOD and LOQ of impurity 
Name of impurity LOD (S/N Ratio) LOQ (S/N Ratio) 
MCA-02 8.17 58.1 
MCA-01 5.92 48.5 
Degradation Impurity 6.17 65.4 




For Repeatability sample containing all impurities at 100% level 
injected for six times and for the intermediate precision sample 
containing all impurities at 50%, 100%, 150% level injected for 
Intraday precision and Interday precision it is injected in 3 sets. 
Sample spiked with all known impurities at 100 % level injected six 
times. All impurity peak area calculated for RSD. % RSD is not more 
than 5. The results are given in table 9. 
 
Table 9: Repeatability data of MCA-02, MCA-01, degradation impurity 
S. No. Concentration PPM (100 % 
level) 
Peak area  
MCA-02 MCA-01 Degradation impurity 
1 1.5 35740 50381 32378 
2 1.5 35948 50581 31318 
3 1.5 34998 49380 32484 
4 1.5 36141 51008 32980 
5 1.5 35889 50451 32035 
6 1.5 36030 50661 32123 
% Mean recovery±SD* 35791±411.17 50410±550.13 32220±553.08 
%RSD 1.15 1.09 1.72 
SD*-Standard deviation, RSD*-Relative standard deviation, Number of experiments (n)–6, Conc*-concentration 
 
Intraday precision 
Intraday precision was performed by injecting stock impurities 
preparations two times (Morning and Evening) on the day by 
maintaining the optimized chromatographic conditions and 
calculate % relative standard deviation of retention time and peak 
areas for macitentan. All impurity area calculated for RSD for 
morning and evening. % RSD is not more than 5. so method is 
precise. The results are given in table 10, 11, and 12. 
 
Table 10: Intraday precision of MCA-02 
50 % level 
Set Level Morning Evening mean±SD* RSD 
1 50% 20432 20124 20278±217.98 1.07 
2 50% 20213 20598 20406±272.24 1.33 
3 50% 20513 20188 20351±229.80 1.13 
100 % level 
Set Level Morning Evening mean±SD* RSD 
1 100% 36981 35991 36486±700.03 1.92 
2 100% 36607 36033 36320±405.87 1.12 
3 100% 36108 35997 36053±78.48 0.22 
150 % level 
Set Level Morning Evening mean±SD* RSD 
1 150% 55814 55125 55470±487.19 0.88 
2 150% 56124 55899 56012±159.09 0.28 
3 150% 55754 55160 55457±420.02 0.76 
 SD*-Standard deviation, RSD*-Relative Standard deviation, Number of experiments (n)-3 
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Table 11: Intraday precision of MCA-01 
50 % level 
Set Level Morning Evening mean±SD* RSD 
1 50% 26013 25981 25997±22.62 0.09 
2 50% 26312 26121 26217±135.05 0.52 
3 50% 26567 26056 26312±361.33 1.37 
100 % level 
Set Level Morning Evening mean±SD* RSD 
1 100% 52254 51789 52022±328.80 0.63 
2 100% 52312 52013 52163±211.42 0.41 
3 100% 52159 51936 52048±157.68 0.30 
150 % level 
Set Level Morning Evening mean±SD* RSD 
1 150% 74718 74135 74427±412.24 0.55 
2 150% 74812 73556 73684±181.01 0.25 
3 150% 74520 74132 74326±274.35 0.37 
 SD*-Standard deviation, RSD*-Relative Standard deviation, Number of experiments (n)-3 
 
Table 12: Intraday precision of degradation impurity 
50 % level 
Set Level Morning Evening mean±SD* RSD 
1 50% 16381 15989 16185±277.18 1.71 
2 50% 16261 15994 16128±188.79 1.17 
3 50% 16221 15931 16076±205.06 1.28 
100 % level 
Set Level Morning Evening mean±SD* RSD 
1 100% 32132 31818 31975±222.03 0.69 
2 100% 32331 32121 32226±148.49 0.46 
3 100% 32880 32590 32735±205.06 0.63 
150 % level 
Set Level Morning Evening mean±SD* RSD 
1 150% 51121 51159 51140±26.87 0.05 
2 150% 52310 51817 52064±348.60 0.62 
3 150% 51731 51234 51483±287.79 0.56 
SD*-Standard deviation, RSD*-Relative standard deviation, Conc*-concentration, Number of experiments (n)–3 
 
Interday precision 
Inter-day precision was performed by injecting stock impurity 
preparations three times into chromatographic system on 2 
different days by maintaining the optimized chromatographic 
conditions and calculate % relative standard deviation of retention 
time and peak areas for macitentan. All impurity area calculated for 
RSD for Day-1 and Day-2.%RSD is not more than 5. so method is 
precise. The results are given in table 13-15. 
Robustness 
According to robustness, there is the minor deliberate change made 
such as in chromatograph parameter with reference of flow rate and 
column temperature. To observe robustness, 100 % level solution 
used. Robustness was checked by changing the flow rate and column 
temperature in the optimized chromatographic condition. This 
method said to be robust as % RSD for each studied factor was found 
to be less than 5. The results are given in table 16, 17, and 18. 
  
Table 13: Interday precision of MCA-02 
50 % level 
Set Level Day-1 Day-2 mean±SD* RSD 
1 50% 20432 20812 20622±268.70 1.30 
2 50% 20213 20787 20500±405.87 1.98 
3 50% 20513 20013 20263±353.55 1.74 
100% level 
Set Level Day-1 Day-2 mean±SD* RSD 
1 100% 36981 37130 37056±105.35 0.28 
2 100% 36607 36917 36762±219.20 0.60 
3 100% 36108 36718 36413±431.33 1.18 
150 % level 
Set Level Day-1 Day-2 mean±SD* RSD 
1 150% 55814 56132 55973±224.8 0.40 
2 150% 56124 56338 56231±151.32 0.27 
3 150% 55754 56124 55939±261.62 0.47 
 SD*-Standard deviation, RSD*-Relative Standard deviation, Number of experiments (n)–3 
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Table 14: Interday precision of MCA-01 
50 % Level 
Set Level Day-1 Day-2 mean±SD* RSD 
1 50% 26013 26454 26234±311.83 1.19 
2 50% 26312 26818 26565±375.79 1.35 
3 50% 26567 26121 26344±315.36 1.20 
100 % level 
Set Level Day-1 Day-2 mean±SD* RSD 
1 100% 52254 52535 52395±198.69 0.38 
2 100% 52312 52117 52215±137.88 0.26 
3 100% 52159 52652 52406±348.60 0.67 
150% level 
Set Level Day-1 Day-2 mean±SD* RSD 
1 150% 74718 74968 74843±176.77 0.24 
2 150% 74812 74528 74873±106.77 0.27 
3 150% 74520 74912 74716±277.18 0.37 
 SD*-Standard deviation, RSD*-Relative Standard deviation, Number of experiments (n)-3 
 
Table 15: Interday precision of degradation impurity 
50 % Level 
Set Level Day-1 Day-2 mean±SD* RSD 
1 50% 16381 16525 16453±101.82 0.62 
2 50% 16261 16434 16348±122.32 0.75 
3 50% 16221 16623 16372±213.54 1.30 
100 % level 
Set Level Day-1 Day-2 mean±SD* RSD 
1 100% 32132 32722 32427±417.19 1.29 
2 100% 32331 32918 32625±415.07 1.27 
3 100% 32880 32581 32731±211.42 0.65 
150% level 
Set Level Day-1 Day-2 mean±SD* RSD 
1 150% 51121 51438 51280±224.15 0.44 
2 150% 52310 51912 52111±281.42 0.54 
3 150% 51731 51934 51833±143.54 0.28 
 SD*-Standard deviation, RSD*-Relative Standard deviation, Number of experiments (n)–3 
 
Table 16: Robustness result of MCA-02 




 1 2 3  
1.3 ml 35312 35138 35381 35842.33±431.91  
1.20 1.5 ml 36013 36133 36131 
1.7 ml 36142 36108 36223 
Coloumn 
temp. 
25 °C 36131 36150 36300 35936.22±352.13  
0.97 30 °C 35648 35830 36101 
35 °C 36130 36138 35998 
SD*-Standard deviation, RSD*-Relative Standard deviation, Number of experiments (n)-3 
 
Table 17: Robustness result of MCA-01 
Parameter Change Area % Mean recovery±SD* RSD 
Flow Rate 
(ml/min) 
 1 2 3  
1.3 ml 50324 50128 50155 50907±546.83  
1.07 1.5 ml 51312 50998 51212 
1.7 ml 51502 51304 51228 
Coloumn 
Temp. 
25 °C 51034 50938 50868 51267.67±258.33  
0.50 30 °C 51341 51554 51344 
35 °C 51334 51558 51438 
SD*-Standard deviation, RSD*-relative standard deviation, number of experiments (n)-3 
 
Table 18: Robustness result of degradation impurity 
Parameter Change Area %Mean recovery±SD* RSD 
Flow rate 
(ml/min) 
 1 2 3  
1.3 ml 33133 32734 33187 35278.67±357.68 1.01 
1.5 ml 33077 33412 33132 
1.7 ml 33814 33581 33781 
Column 
temp. 
25 °C 32812 33018 32918 33072.44±176.45 0.53 
30 °C 33118 33418 33216 
35 °C 33141 32998 33013 
SD*-Standard deviation, RSD*-relative standard deviation, Number of experiments (n)-3 
Trivedi et al. 




All the parameters and results were found within the acceptance limit as 
given in the validation protocol. So we can conclude that the developed 
RP-HPLC Method was selective, specific, sensitive, linear, accurate, 
precise, and robust. Therefore the method is found to be specific for 
macitentan’s related substances with good resolution. It can be applied 
to the forced degradation study. So the proposed method can be used in 
the pharmaceutical analysis for Forced degradation study and routine 
quality control samples of macitentan Tablets. 
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